Literature DB >> 14756800

Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.

Patricia A Trimmer1, M Kathleen Borland, Paula M Keeney, James P Bennett, W Davis Parker.   

Abstract

Many models of Parkinson's disease (PD) have succeeded in replicating dopaminergic neuron loss or alpha-synuclein aggregation but not the formation of classical Lewy bodies, the pathological hallmark of PD. Our cybrid model of sporadic PD was created by introducing the mitochondrial genes from PD patients into neuroblastoma cells that lack mitochondrial DNA. Previous studies using cybrids have shown that information encoded by mitochondrial DNA in patients contributes to many pathogenic features of sporadic PD. In this paper, we report the generation of fibrillar and vesicular inclusions in a long-term cybrid cell culture model that replicates the essential antigenic and structural features of Lewy bodies in PD brain without the need for exogenous protein expression or inhibition of mitochondrial or proteasomal function. The inclusions generated by PD cybrid cells stained with eosin, thioflavin S, and antibodies to alpha-synuclein, ubiquitin, parkin, synphilin-1, neurofilament, beta-tubulin, the proteasome, nitrotyrosine, and cytochrome c. Future studies of these cybrids will enable us to better understand how Lewy bodies form and what role they play in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756800     DOI: 10.1046/j.1471-4159.2003.02168.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

Review 2.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

3.  Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

Authors:  Paula M Keeney; Caitlin K Quigley; Lisa D Dunham; Christina M Papageorge; Shilpa Iyer; Ravindar R Thomas; Kathleen M Schwarz; Patricia A Trimmer; Shaharyar M Khan; Francisco R Portell; Kristen E Bergquist; James P Bennett
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

Review 4.  Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration.

Authors:  Rodolphe Perrot; Raphael Berges; Arnaud Bocquet; Joel Eyer
Journal:  Mol Neurobiol       Date:  2008-07-23       Impact factor: 5.590

Review 5.  Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration.

Authors:  Romana Fato; Christian Bergamini; Serena Leoni; Paola Strocchi; Giorgio Lenaz
Journal:  Neurochem Res       Date:  2008-06-06       Impact factor: 3.996

6.  A cybrid cell model for the assessment of the link between mitochondrial deficits and sporadic Parkinson's disease.

Authors:  Daniela M Arduíno; A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Methods Mol Biol       Date:  2015

Review 7.  Mitochondria in neurodegeneration.

Authors:  E Lezi; Russell H Swerdlow
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

Authors:  Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2010-04-13       Impact factor: 14.195

9.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

10.  Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy.

Authors:  Patricia A Trimmer; Kathleen M Schwartz; M Kathleen Borland; Luis De Taboada; Jackson Streeter; Uri Oron
Journal:  Mol Neurodegener       Date:  2009-06-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.